See more : RF Acquisition Corp II Unit (RFAIU) Income Statement Analysis – Financial Results
Complete financial analysis of Alpha Tau Medical Ltd. (DRTS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alpha Tau Medical Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SILK Laser Australia Limited (SLA.AX) Income Statement Analysis – Financial Results
- Archer Aviation Inc. (ACHR) Income Statement Analysis – Financial Results
- Classic Minerals Limited (CLZ.AX) Income Statement Analysis – Financial Results
- HydrogenOne Capital Growth plc (HGEN.L) Income Statement Analysis – Financial Results
- Tern Plc (TERNF) Income Statement Analysis – Financial Results
Alpha Tau Medical Ltd. (DRTS)
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.07M | 979.00K | 776.00K | 86.00K | 0.00 |
| Gross Profit | -1.07M | -979.00K | -776.00K | -86.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 26.42M | 20.89M | 11.45M | 7.54M | 6.64M |
| General & Administrative | 7.33M | 10.27M | 1.86M | 1.41M | 977.00K |
| Selling & Marketing | 1.92M | 974.00K | 482.00K | 288.00K | 397.00K |
| SG&A | 9.26M | 11.25M | 2.34M | 1.70M | 1.37M |
| Other Expenses | -72.20M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -35.68M | 32.14M | 13.79M | 9.24M | 8.01M |
| Cost & Expenses | -35.68M | 32.14M | 13.79M | 9.24M | 8.01M |
| Interest Income | 4.76M | 1.79M | 211.00K | 613.00K | 776.00K |
| Interest Expense | 39.00K | 1.77M | 13.27M | 217.00K | 0.00 |
| Depreciation & Amortization | 1.07M | 979.00K | 776.00K | 86.00K | 66.00K |
| EBITDA | -28.03M | -32.74M | -13.22M | -9.16M | -7.94M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 35.68M | -32.14M | -13.79M | -9.24M | -8.01M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -64.82M | -1.61M | -13.47M | 520.00K | -308.00K |
| Income Before Tax | -29.14M | -33.74M | -27.26M | -8.72M | -8.32M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 16.00K | 20.00K | 7.00K | 158.00K | 146.00K |
| Net Income | -29.16M | -33.76M | -27.27M | -8.88M | -8.46M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.42 | -0.53 | -0.67 | -0.22 | -0.13 |
| EPS Diluted | -0.42 | -0.53 | -0.67 | -0.22 | -0.13 |
| Weighted Avg Shares Out | 69.38M | 63.53M | 40.53M | 40.43M | 67.62M |
| Weighted Avg Shares Out (Dil) | 69.38M | 63.53M | 40.53M | 40.43M | 67.62M |
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with liver cancer metastases has...
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present at the following...
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview...
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update
- Positive interim safety and feasibility data from pancreatic cancer study in Montreal , with initial signs of potential dose response findings -
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate at the Barclays 26th Annual...
Is Alpha Tau Medical (DRTS) Stock Outpacing Its Medical Peers This Year?
Here is how Alpha Tau Medical Ltd. (DRTS) and Regeneron (REGN) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for January 8th
AKYA, DRTS and TRUP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024.
New Strong Buy Stocks for January 8th
TIMB, AKYA, DRTS, TRUP and QSG have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024.
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- The overview presentation will review some of the Company's recent achievements, including highly promising interim results from the Company's pancreatic cancer safety and feasibility trial as well as robust long-term data analyzed across four clinical trials -
Source: https://incomestatements.info
Category: Stock Reports